spacer
home > pmps > summer 2002 > surfactant - therapy, excipient and humectant
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Surfactant - Therapy, Excipient and Humectant

Surfactant replacement therapy for the treatment and prevention of neonatal respiratory distress syndrome (RDS) has been a major success story in respiratory care over the past decade. Animal-derived and synthetic surfactants are now available commercially throughout the world and there are several others in development. Surfactants are currently providing a miracle-like contribution towards dramatically improving the survival rate of critically ill infants with less than 30 weeks' gestation.

However, these advances may well be overshadowed by progressions in formulation technology that will make synthetic surfactants available for a number of other conditions. After the first few days from birth, adequate surfactant function is vitally important for optimal lung function. Surfactant dysfunction arising from a variety of mechanisms may contribute to a number of conditions. Surfactant therapy has been examined in a number of these with varying effects.

They include acute respiratory distress syndrome (ARDS) (1), respiratory syncytial virus bronchiolitis in infants (2), chronic bronchitis (3), chronic obstructive pulmonary disease (4), asthma (5,15), respiratory infections (6) and cystic fibrosis (7). Understanding the different roles of endogenous surfactant and the dysfunctions observed in these conditions must be a consideration when designing an effective therapy. In addition to opposing surface tension forces within the alveolus to maintain airway stability, surfactant has also been reported to promote mucociliary clearance (8), bind or neutralise aeroallergens, pollens, bacteria and other particulates (9,10), and oppose airway oedema (11).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Derek Woodcock, Technical Services Director for Britannia Pharmaceuticals Ltd. Derek Woodcock is Technical Services Director for Britannia Pharmaceuticals Ltd., where he is responsible for the company's medical, clinical and development projects. Derek oversees specific technical projects from the formulation definition stage to clinical evaluation and registration.
He currently has technical responsibility for establishing Britannia's phospholipid and surfactant research, which also covers some novel delivery technologies for internal and out-licensing opportunities. In addition to technical expertise, he has particular knowledge in the area of drug licensing and registration.
Derek gained a BPharm degree in Pharmacy from The School of Pharmacy in London and an MBA from Kingston University. He is also a registered Pharmacist.

spacer
Derek Woodcock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement